PRESS RELEASE published on 04/08/2024 at 23:01, 6 months 10 days ago Biophytis launches OBA phase 2 clinical study in obesity with BIO101 (20-hydroxyecdysone) Biophytis annonce ses résultats financiers 2023 et lance l'étude clinique de phase 2 OBA dans l'obésité avec BIO101 (20-hydroxyecdysone), confirmant son avancement dans le développement de traitements innovants Biophytis Résultat Annuel Étude Clinique BIO101 Obésité
PRESS RELEASE published on 04/08/2024 at 23:01, 6 months 10 days ago Biophytis announces its 2023 financial results and provides an update on its business activities Biophytis announces 2023 financial results & business update. Highlights: progress in clinical programmes, funding secured till 2025. Key focus on SARA, OBA, COVA, OBA, and MYODA programs Financial Results Biophytis 2023 Funding Clinical Programmes
PRESS RELEASE published on 04/08/2024 at 23:00, 6 months 10 days ago Biophytis launches OBA phase 2 clinical study in obesity with BIO101 (20-hydroxyecdysone) Biophytis launches OBA phase 2 clinical study with BIO101 (20-hydroxyecdysone) for obesity treatment, targeting muscle preservation and promising results. Clinical program expected to start mid-2024 Biophytis Obesity Treatment BIO101 OBA Phase 2 Muscle Preservation
PRESS RELEASE published on 04/08/2024 at 23:00, 6 months 10 days ago Biophytis lance l'étude clinique de phase 2 OBA dans l'obésité avec BIO101 (20-hydroxyecdysone) Biophytis lance l'étude clinique de phase 2 OBA dans l'obésité avec BIO101 (20-hydroxyecdysone). Résultats prometteurs pour traiter la perte musculaire liée à l'obésité. Marché potentiel de 100 milliards de dollars d'ici 2030 Biophytis Étude Clinique BIO101 Obésité Perte Musculaire
BRIEF published on 04/04/2024 at 23:05, 6 months 14 days ago Biophytis annonce le succès de son Assemblée Générale du 2 avril 2024 Biophytis Biotechnologie Assemblée Générale Développement Clinique Maladies Liées À L'âge
BRIEF published on 04/04/2024 at 23:05, 6 months 14 days ago Biophytis Announces Unanimous Approval in General Meeting Biophytis Shareholder Approval General Meeting RuvembriTM Age-related Diseases
PRESS RELEASE published on 04/04/2024 at 23:00, 6 months 14 days ago RESULTS OF THE COMBINED GENERAL MEETING ON APRIL 2, 2024 Biophytis announces all resolutions presented at the combined general meeting on April 2, 2024, have been adopted, including financial delegations. Shareholders' mobilization ensured a quorum of nearly 30% Shareholders Biophytis General Meeting Resolutions Approval
PRESS RELEASE published on 04/04/2024 at 23:00, 6 months 14 days ago RÉSULTATS DE L’ASSEMBLÉE GÉNÉRALE MIXTE DU 2 AVRIL 2024 Biophytis annonce l'adoption de toutes les résolutions lors de son Assemblée Générale Mixte du 2 avril 2024. Les résultats sont disponibles sur leur site. Détails sur les activités et avertissement inclus Biophytis Développement Biotechnologie Assemblée Générale Résultats
REGULATED PRESS RELEASE published on 04/04/2024 at 23:00, 6 months 14 days ago RÉSULTATS DE L’ASSEMBLÉE GÉNÉRALE MIXTE DU 2 AVRIL 2024 Biophytis annonce l'approbation de toutes les résolutions présentées lors de son Assemblée Générale Mixte. Les détails des votes sont disponibles en ligne. En savoir plus sur BIOPHYTIS et ses candidats-médicaments Biophytis Développement Assemblée Générale Resolutions Candidats-médicaments
REGULATED PRESS RELEASE published on 04/04/2024 at 23:00, 6 months 14 days ago RESULTS OF THE COMBINED GENERAL MEETING ON APRIL 2, 2024 Biophytis announces approval of all resolutions at the Combined General Meeting held on April 2, 2024, with significant shareholder turnout. The Company specializes in therapeutics for age-related diseases Shareholders Biophytis Therapeutics Combined General Meeting Age-related Diseases
Published on 10/19/2024 at 00:20, 8 hours 18 minutes ago Bermuda Carbon Commission Debuts at Green Overseas Climate Finance Forum: Setting a Global Standard for Blue Carbon Innovation
Published on 10/18/2024 at 20:00, 12 hours 38 minutes ago Western Alaska Minerals Announces Grant of Restricted Share Units
Published on 10/18/2024 at 15:00, 17 hours 38 minutes ago Namibia Critical Metals Receives Environmental Clearance Certificate for Mining Activities on its Lofdal Heavy Rare Earth Project
Published on 10/18/2024 at 14:31, 18 hours 7 minutes ago Vicinity Motor Corp. Receives Notice from RBC of Intent to File Receivership Order on Monday, October 21, 2024
Published on 10/18/2024 at 14:00, 18 hours 38 minutes ago Bold Ventures Announces Final Closing of Non-Brokered Private Placement and Insider Subscriptions
Published on 10/19/2024 at 05:59, 2 hours 38 minutes ago Policy Address by Hong Kong SAR’s Chief Executive John Lee: Improving People’s Livelihood in Pursuit of Happiness
Published on 10/18/2024 at 22:18, 10 hours 20 minutes ago Investor Materials Ahead of Trading Resumption
Published on 10/18/2024 at 22:14, 10 hours 23 minutes ago EQS-Adhoc: aap Implantate AG: Step-by-step restart of IT systems
Published on 10/18/2024 at 19:45, 12 hours 53 minutes ago Springer Nature - Exercise & Post-Stabilisation
Published on 10/18/2024 at 18:30, 14 hours 8 minutes ago For the track and the road: The new 911 GT3 and 911 GT3 with Touring package
Published on 10/18/2024 at 18:55, 13 hours 43 minutes ago LDC : Accord en vue de l’acquisition de European Convenience Food (ECF) en Allemagne.
Published on 10/18/2024 at 18:55, 13 hours 43 minutes ago LDC : Entry into an agreement for the acquisition of European Convenience Food (ECF) in Germany.
Published on 10/18/2024 at 17:45, 14 hours 53 minutes ago TINC investeert in de veilige en vlotte doorstroming van de ringweg rond Brussel (B)
Published on 10/18/2024 at 17:45, 14 hours 53 minutes ago TINC invests in safe and smooth traffic on the Brussels ring road (B)
Published on 10/18/2024 at 17:45, 14 hours 53 minutes ago TINC invests in safe and smooth traffic on the Brussels ring road (B)